|
|
|
| Dealmaking and Industry Outlook: Neurological Disease |
|
| Table of Contents Published: 2009/11 |
| The plethora of recent reports of new genes and pathways linked to neurological diseases shows that the underlying causes of these diseases are far from certain; as a result, therapeutic strategies in effect today may soon be superseded by new approaches. ... |
| Pharmaceutical Pricing and Reimbursement in India |
|
| Table of Contents Published: 2009/09 |
| Faced with a dramatic slowdown in sales in mature pharmaceutical markets, multinational pharmaceutical companies are looking to substantially increase their sales in India and other emerging markets. The Indian market is growing by more than 10% per year, ... |
| Neurological Disease: Early-Stage R&D and Dealmaking |
|
| Table of Contents Published: 2009/08 |
| How can early-stage R&D efforts be positioned to tap the remaining opportunity in the neurology drug market? Although brimming with potential, neurology drug development is also rife with unique challenges that many companies and agents have been unable t ... |
| The Neurology Pipeline: A Strategic Review |
|
| Table of Contents Published: 2009/08 |
| Mega-blockbuster status would be quick and sure for any safe, effective agent that prevents the death and damage of neurons associated with neurodegenerative diseases. The potential of such a neuroprotectant is one of the motivations for the 188 companies ... |
| The Psychiatric Disease Pipeline: A Strategic Review |
|
| Table of Contents Published: 2009/07 |
| Numbers tell the story in psychiatric disease drug development: almost 300 recognized indications, 28% 12-month prevalence that yields large patient populations, strong 7.5% annual sales growth in recent years, sustained franchise sales, tolerance for use ... |
| Brands & Strategies: Alzheimer's Disease |
|
| Table of Contents Published: 2009/06 |
| In 2007, the Alzheimer' s disease (AD) market, valued at more than $3 billion in the United States, Europe, and Japan, was led by sales of Eisai/Pfizer' s Aricept. The growth of all the currently available agents will decline by the end of our forecast, a ... |
| Key Trends Fueling the Boom in Genetic Testing |
|
| Table of Contents Published: 2009/06 |
| Progress aptly describes the expanding field of genetic testing. The field is more than finding linkages of genes with diseases: it encompasses technologies that have made it easier to quickly and more efficiently discover genetic markers that predict dis ... |
| Mega-Mergers: Executing Change in the Pharma Industry |
|
| Table of Contents Published: 2009/06 |
| If consolidation is so advantageous for boosting a pharma company to a new level of productivity, why has Pfizer engaged in not just one but three mega-mergers in the past ten years: $92.3 billion for Warner-Lambert in 2000, $60 billion for Pharmacia in 2 ... |
| New Strategies in Academic-Industry Collaborations |
|
| Table of Contents Published: 2009/06 |
| Major pharmaceutical companies are showing increased interest in directly sponsoring academic research to access innovation and fill dwindling pipelines. Recent agreements involve higher levels of collaboration and funding, are broader in scope, and focus ... |
| Pharmaceutical Pricing and Reimbursement in China |
|
| Table of Contents Published: 2009/06 |
| With a growth rate of more than 20% per year, the Chinese pharmaceutical market is set to become the third largest in the world in 2011. A radical healthcare reform package recently unveiled by the government will more than double public healthcare expend ... |
| Dealmaking and Industry Outlook: Antivirals |
|
| Table of Contents Published: 2009/05 |
| The infamous mutability of viruses has long challenged antiviral drug developers, but complete genome sequences are now known for thousands of viruses, and the viral proteins encoded in these sequences are being used as targets for novel antiviral develop ... |
| Dealmaking and Industry Outlook: Geriatric Diseases |
|
| Table of Contents Published: 2009/05 |
| Rising Medicare costs driven by the aging baby boomers will, within the next few years, propel public national health expenditures in the United States above private national health expenditures for the first time ever. Increasing expenditures are just on ... |
| The Immune/Inflammatory Pipeline: A Strategic Review |
|
| Table of Contents Published: 2009/05 |
| The current immune/inflammatory pipeline is over 375 drugs strong, with approximately 250 companies involved in these agents' development. Yet, despite this robust pipeline size, Decision Resources analysts do not believe that any one agent in development ... |
| Drug Benefit Trends in the United States |
|
| Table of Contents Published: 2009/03 |
| After many years of vigorous growth, the world' s dominant pharmaceutical market faces unprecedented challenges in the near future. This report, which features 27 fi gures and tables, analyzes recent drug benefi t trends and assesses the outlook and impli ... |
| Formulary Decision Making in the United States |
|
| Table of Contents Published: 2009/03 |
| The U.S. pharmaceutical industry is facing the worst combination of pressures in memory - the most severe recession in decades, a dramatic slowdown in pharmaceutical sales, a new U.S. administration intent on slashing healthcare costs, and a host of block ... |
| Brands & Strategies: Rheumatoid Arthritis |
|
| Table of Contents Published: 2008/12 |
| The RA market will see significant growth over our five-year forecast period, reaching $11 billion in 2012. Five new biological agents will join the six currently marketed biological therapies, heightening competition in an increasingly crowded market. ... |
| What to Do When the R&D Pipeline Runs Dry |
|
| Table of Contents Published: 2008/12 |
| The pharmaceutical industry has been coping with declining R&D productivity for more than two decades and is under signifi cant pressure to improve its bottom line and growth prospects. Industry stakeholders are seriously discussing whether companies shou ... |
| Brands & Strategies: Lipid-Modifying Agents |
|
| Table of Contents Published: 2008/11 |
| The lipid-modifying drug market is highly competitive, currently comprising at least 14 brands in seven major drug classes, and extremely lucrative, with major-market sales surpassing $24 billion in 2007. However, we forecast sales to decline by 4% annual ... |
| Meeting the Challenges of Manufacturing Biosimilars |
|
| Table of Contents Published: 2008/11 |
| Branded biologics have, until recently, been immune to generics competition; however, the approval of biosimilars in Europe heralds a changing landscape. Legislation enabling the approval of biosimilars is stalled in the U.S. Congress but could pass in 20 ... |
| Brands & Strategies: Asthma |
|
| Table of Contents Published: 2008/10 |
| The asthma market is saturated with numerous drugs that effectively treat the majority of patients. In 2007, asthma sales in the seven major markets under study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) totaled $10.9 billio ... |
| Key Markets in Medicare Part D |
|
| Table of Contents Published: 2008/08 |
| Medicare Part D, the outpatient prescription drug benefit introduced in January 2006, had an immediate impact on the U.S. pharmaceutical market and now accounts for almost one-fifth of prescription drug sales. Cardiovascular diseases, metabolic disorders, ... |
| Targeting Kinases for Drug Discovery |
|
| Table of Contents Published: 2008/04 |
| Protein kinases - intracellular enzymes that modulate cellular functions - play a pivotal role in the signal transduction processes that regulate many key biological processes. Abnormalities in these signal transduction pathways are implicated in the etio ... |
| How to Get Ahead with Pharmacogenomics |
|
| Table of Contents Published: 2008/03 |
| The blockbuster business model is, of course, still relevant to the pharmaceutical industry, but at the same time, companies must adopt technologies that will enable them to develop better drugs-value-added drugs that can command the prices capable of pro ... |
| Brands & Strategies: Atypical Antipsychotics |
|
| Table of Contents Published: 2008/02 |
| The atypical antipsychotics market in the United States, Europe, and Japan, valued at an estimated $15.9 billion in sales at ex-manufacturer level in 2007, is expected to expand to over $17.8 billion by 2011, before shrinking to $13.5 billion in 2012. ... |
| Brands & Strategies: Colorectal Cancer |
|
| Table of Contents Published: 2007/12 |
| In 2006, the CRC market, valued at over $7 billion in the US, Europe, and Japan, was led by the chemotherapeutic platinum agent, Sanofi-Aventis' Eloxatin. Five existing drug classes, including the recently introduced targeted EGFR and VEGFR inhibitors, ma ... |
| Brands & Strategies: Non-Small-Cell Lung Cancer |
|
| Table of Contents Published: 2007/12 |
| In 2006, the NSCLC market, valued at over $3 billion in the US, Europe, and Japan, was led by the chemotherapeutic taxane, Sanofi-Aventis' Taxotere. Five existing drug classes, including the recently introduced targeted EGFR and VEGFR inhibitors, make for ... |
| Emerging Drug Targets in Alzheimer's Disease |
|
| Table of Contents Published: 2007/12 |
| The lack of effective treatments for Alzheimer' s disease (AD) and an aging population create an enormous opportunity for disease-modifying drugs. Competition to develop new drugs for AD is in fact fi erce, and the effi cacy bar for current AD therapies i ... |
| Outsourcing Drug Discovery: China and India |
|
| Table of Contents Published: 2007/11 |
| Driven by the need to improve R&D productivity and effi ciency and the desire to access untapped markets, global pharmaceutical companies have increasingly offshored and outsourced operations to CROs in China and India. A wide array of factors, however, c ... |
| Brands & Strategies: Osteoporosis |
|
| Table of Contents Published: 2007/10 |
| The osteoporosis market has traditionally been dominated by the bisphosphonate drug class, championed by Merck' s once-weekly Fosamax (alendronate) and Procter & Gamble[P&G]/Sanofi-Aventis' Actonel (risedronate). This will change dramatically over the for ... |
|
 Top
|
|
View Cart
